Bridgefront Capital LLC Takes $680,000 Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Bridgefront Capital LLC bought a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 17,264 shares of the company's stock, valued at approximately $680,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new position in shares of CRISPR Therapeutics during the third quarter worth approximately $40,000. Highline Wealth Partners LLC acquired a new position in CRISPR Therapeutics during the 4th quarter worth $39,000. Western Pacific Wealth Management LP grew its stake in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after purchasing an additional 500 shares in the last quarter. Spire Wealth Management increased its holdings in shares of CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after purchasing an additional 1,482 shares during the period. Finally, MCF Advisors LLC bought a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at about $80,000. Institutional investors own 69.20% of the company's stock.

Wall Street Analyst Weigh In

CRSP has been the topic of several research analyst reports. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price on the stock in a research note on Wednesday, February 12th. Morgan Stanley boosted their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a report on Friday, February 14th. Stifel Nicolaus cut their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research report on Thursday, February 13th. Barclays dropped their price objective on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research note on Friday. Finally, JMP Securities restated a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $71.58.

Insider Buying and Selling

In other CRISPR Therapeutics news, Director John Greene purchased 7,000 shares of the company's stock in a transaction dated Wednesday, February 26th. The shares were bought at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the purchase, the director now directly owns 7,000 shares in the company, valued at $313,950. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,381 shares of company stock worth $1,608,243. 4.30% of the stock is owned by company insiders.

CRISPR Therapeutics Stock Down 1.4 %

Shares of CRSP traded down $0.52 during mid-day trading on Friday, reaching $35.62. The company's stock had a trading volume of 1,737,782 shares, compared to its average volume of 1,669,274. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $67.88. The company has a market cap of $3.08 billion, a price-to-earnings ratio of -8.15 and a beta of 1.88. The business has a fifty day moving average of $38.31 and a 200 day moving average of $42.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The business's quarterly revenue was up 71.6% on a year-over-year basis. During the same period in the previous year, the company earned ($1.43) earnings per share. On average, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.